| Name | Theracryf |
|---|---|
| Epic | TCF |
| Isin | GB00BSVYN304 |
| Industry | n/a |
| Latest share price | 0.52p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.21 | Debt ratio | n/a |
| Shares in issue | 427.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | n/a |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | n/a | 52-week high / low | 0.52p / 1.85p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Theracryf |
|---|---|
| Address | Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom, L3 5RF |
| Telephone | |
| Website | http://www.theracryf.com/ |
| Director | Position |
|---|---|
| Dr Huw Jones | CEO |
| Mr Toni Hänninen | CFO |
| Dr Susan (Sue) Foden | Interim Chairman |
| Dr Alan Barge | Independent Non-Executive Director |
| Assets |
|---|
| Liabilities |
|---|
| Net assets |
|---|
| Equity |
|---|
| Income |
|---|